Control of adverse drug reactions in HIV/AIDS antiretroviral treatment with interchangeable medicines
Abstract
Review on assessment data of ADR, which must be monitored during antiretroviral therapy in patients with HIV/AIDS are presented. Questions of drug safety acquire particular importance in conducting pharmacotherapy of the most socially significant diseases, which include HIV/AIDS. Currently there is a sufficient number of generic drugs for antiretroviral therapy, which form the basis for affordable health care. The correlation of efficacy and safety of generic drugs, their interchangeability assessment require constant study of the antiretroviral drugs influence on various systems of the body. Particular attention should be given to the cardiovascular disorders and hepatotoxicity.
About the Authors
M. V. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products; I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. B. Prokofiev
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
A. S. Podymova
Sverdlovsk Regional AIDS Prevention and Control Center
Russian Federation
Russian Federation
N. G. Berdnikova
I. M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
S. Yu. Serebrova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
E. Yu. Demchenkova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
References
1. Alfonso-Cristancho R, Andia T, BarbosaT, Watanabe JH. Definition and classification of generic drugs across the world. Appl. HealthEcon. Health- Policy 2015; 13(1): 5–11.
2. Bhatnagar P, Dhote V, Mahajan SC, Mishra PK, Mishra DK. Solid dispersion in pharmaceutical drug development: From basics to clinical applications. Curr. Drug. Deliv. 2014; 11(2): 155–171.
3. Breitenbach J. Melt extrusion can bring new benefits to HIV therapy. Am. J. Drug. Deliv. 2006; 4(2): 61–64.
4. Shah N. Amorphous solid dispersions: Theory and practice. London: Springer; 2014.
5. Zucman D, Camara S, Gravisse J, Dimi S, Vasse M, Goudjo A, Choquet M, Peytavin G. Generic antiretroviral drugs in developing countries: Friends or foes? AIDS 2014; 28(4): 607–609.
6. Chistyakov VV. Certain aspects of the bioanalytical part of drug bioequivalence studies. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2013; (3): 24–28 (in Russian).
7. Federal Law 2014 Dec 12 ¹ 429-FZ. Available from: http://kremlin.ru/acts/bank/39223 (in Russian).
8. Nelson M, Hill A, van Delft Y, Moecklinghoff C. Etravirine as a switching option for patients with HIV RNA suppression: A review of recent trials. AIDS Res. Treat. 2014. doi: 10.1155/2014/636584.
9. Yengalycheva GN, Syubaev RD, Vasiliev AN, et al. Drug pharmocologocal safety evaluation in preclinical dtudies. Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products 2013; (1): 10–13 (in Russian).
10. Glagolev SV, Olefir YuV, Romanov BK, Alyautdin RN. Guidelines for the planning and implementing of pharmacovigilance systems audit. Safety and Risk of Pharmacotherapy 2016; 3: 5–13 (in Russian).
11. Newman A. Pharmaceutical amorphous solid dispersions. New Jersey: John Wiley and Sons; 2015.
12. Garren KW, Rahim S, Marsh K, Morris JB. Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model. J. Pharm. Sci. 2009; 99(2). doi:10.1002/jps.21712.
13. Kakuda TN, Schöller-Gyüre M, Workman C è äð. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1- infected patients. Antivir. Ther. 2008; 13(5): 655–661.
14. Ramesh K, Chandra Shekar B, Khadgapathi P, Bhikshapathi DVRN. A Comparative Study of Etravirine Solid Dispersions using Hot-Melt Extrusion and Spray Drying Technique. Am. J. Pharm. Tech. Res. 2014; 4(6): 595–617.
15. Bonfanti P, Landonio S, Ricci E, et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J. Acquir. Immune. Defic. Syndr. 2001; 167: 316–8.
16. Wit FW,Weverling GJ,Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23–31.
17. Flexner C. HIV protease inhibitors. ¹ Engl J Med. 1998; 338: 1281–1292.
18. Gisolf HE, Dreezen C, Danner SA, et al. Risk factors for hepatotoxicity in HIV-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin. Infect. Dis. 2000; 31: 1234–1239.
19. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz- containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182–9.
20. Lapadula G, Costarelli S, Castelli F. Risk of liver enzyme elevation during treatment with ritonavir-boosted protease inhibitors among HIV-monoinfected and HIV/HCV coinfected patients. Abstract book 14th European AIDS Conference 2013; PE11/6.
21. Petan JA, UndreN, First MR, Saito K, Ohara T, Iwabe O, Mimura H, Suzuki M, Kitamura S. Physiochemical properties of generic formulations of tacrolimus in mexico. Transplant. Proc. 2008; 40(5): 1439–1442.
22. Velts NYu, Alyautdin RN, Kazakov AS, Bukatina TM, Darmostukova MA. The rules of good laboratory practice. Safety and Risk of Pharmacotherapy 2016;(1): 28–32 (in Russian).
23. Kakuda TN, Schöller-Gyüre M, Workman C, Arasteh K, Pozniak AL, De Smedt G. Beets G, Peeters M, Vandermeulen K, Woodfall J, Richard MW. Singleand multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1- infected patients. Antivir. Ther. 2008;13 (5): 655–661.
24. Sabin CA. Pitfalls of assessing hepatotoxicity in trials and observational cohorts. Clin. Inf. Dis. 2004; 38: 55–64.
25. Rubio R, Serrano O, Carmena J. Effect of simplification from protease inhibitors to boosted atazanavir based regimens in real-life conditions. HIV Med. 2010; 11(9): 545–553.
26. Phillips EJ, Mallal SA. Pharmacogenetics and the potential for the individualization of antiretroviral therapy. CurrOpin Infect Dis 2008; 21(1): 16–24.
27. Ramesh K, Chandra Shekar B, Khadgapathi P, Bhikshapathi DVRN. A Comparative Study of Etravirine Solid Dispersions using Hot-Melt Extrusion and Spray Drying Technique. Am. J. Pharm. Tech. Res. 2014; 4(6): 595–617.
28. Katlama C, Clotet B, Mills A. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. AntivirTher 2010; 15: 1045–1052.
29. Abrescia N, Abbraccio M, Figoni M, et al. Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment naý¨ve female AIDS patient without hepatitis virus co-infection. J AntimicrobChemother 2002; 50: 763–765.
Review
For citations:
Zhuravleva M.V., Prokofiev A.B., Podymova A.S., Berdnikova N.G., Serebrova S.Yu., Demchenkova E.Yu. Control of adverse drug reactions in HIV/AIDS antiretroviral treatment with interchangeable medicines. Safety and Risk of Pharmacotherapy. 2017;5(3):126-132. (In Russ.)
Views:
1001
Email this article 